Biora Therapeutics Stock Price, News & Analysis (NASDAQ:BIOR) $1.35 +0.11 (+8.87%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.24▼$1.6150-Day Range$1.21▼$2.6252-Week Range$1.18▼$7.68Volume12.23 million shsAverage Volume442,928 shsMarket Capitalization$32.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Biora Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.55) to ($2.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.37 out of 5 starsMedical Sector901st out of 954 stocksPharmaceutical Preparations Industry419th out of 439 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Biora Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.92% of the float of Biora Therapeutics has been sold short.Short Interest Ratio / Days to CoverBiora Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biora Therapeutics has recently increased by 28.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiora Therapeutics does not currently pay a dividend.Dividend GrowthBiora Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOR. Previous Next 2.3 News and Social Media Coverage News SentimentBiora Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders23.18% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.79% of the stock of Biora Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biora Therapeutics are expected to grow in the coming year, from ($4.55) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biora Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biora Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Biora Therapeutics Stock (NASDAQ:BIOR)Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Read More BIOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOR Stock News HeadlinesDecember 1, 2023 | msn.comFDA clears IND for Biora Therapeutics’s ulcerative colitis drugDecember 1, 2023 | msn.comWhy Is Chronic Disease Focused Biora Therapeutics Stock Trading Higher Today?December 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 30, 2023 | markets.businessinsider.comFDA Clears Biora's IND Application For BT-600 In Ulcerative Colitis Treatment; Stock SurgesNovember 30, 2023 | marketwatch.comBiora Therapeutics Application for Ulcerative Colitis Treatment Gets FDA ClearanceNovember 30, 2023 | msn.comFDA clears Biora to begin Phase 1 testing of ulcerative colitis treatmentNovember 30, 2023 | marketwatch.comBiora Therapeutics Shares Rise 64% After FDA Clears Application for Ulcerative Colitis TreatmentNovember 30, 2023 | finance.yahoo.comBiora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative ColitisDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 16, 2023 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | msn.comBIOR: 3Q:23 ResultsNovember 14, 2023 | finance.yahoo.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comQ3 2023 Biora Therapeutics Inc Earnings CallNovember 13, 2023 | finance.yahoo.comBiora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | msn.comBiora Therapeutics GAAP EPS of -$4.89 misses by $3.96November 13, 2023 | benzinga.comRecap: Biora Therapeutics Q3 EarningsNovember 13, 2023 | finance.yahoo.comBiora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 12, 2023 | markets.businessinsider.comBiora Therapeutics earnings: here's what Wall Street expectsNovember 10, 2023 | benzinga.comEarnings Outlook For Biora TherapeuticsNovember 6, 2023 | finance.yahoo.comBiora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateNovember 1, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOROctober 31, 2023 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Submits Updated IND Application for BT-600October 30, 2023 | msn.comBiora submits updated IND application to FDA for BT-600October 30, 2023 | finance.yahoo.comBiora Therapeutics Submits Updated IND Application for BT-600October 24, 2023 | msn.comBiora submits updated IND application for ulcerative colitis drug/device trialOctober 23, 2023 | msn.comBiora IND for BT-600 delayed due to FDA request for more infoOctober 23, 2023 | finance.yahoo.comBiora Therapeutics to Submit Updated IND Application for BT-600See More Headlines Receive BIOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOR CUSIPN/A CIK1580063 Webwww.bioratherapeutics.com Phone833-727-2841FaxN/AEmployees54Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,160,000.00 Net Margins-55,269.39% Pretax Margin-677,261.06% Return on EquityN/A Return on Assets-125.67% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$310,000.00 Price / Sales103.21 Cash FlowN/A Price / Cash FlowN/A Book Value($5.01) per share Price / Book-0.27Miscellaneous Outstanding Shares23,700,000Free Float18,209,000Market Cap$32.00 million OptionableOptionable Beta1.22 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Aditya P. Mohanty M.B.A. (Age 56)CEO & Director Comp: $858.82kMr. Eric d'Esparbes (Age 55)Executive VP & CFO Comp: $651.91kMr. Clarke Neumann J.D. (Age 59)Senior VP, General Counsel & Secretary Comp: $624.13kEric FoxVP of Finance & Accounting & TreasurerMr. Troy Seelye (Age 59)Chief Information Officer Mr. George Gianakopoulos (Age 62)Senior Vice President of Sales Ms. Robyn HattonHead of Human ResourcesMr. Kevin Howe Ph.D.Senior VP of Strategic OperationsDr. Sharat Singh Ph.D. (Age 64)Head of Research Dr. Paul Shabram M.B.A.Head of Technical OperationsMore ExecutivesKey CompetitorsRezoluteNASDAQ:RZLTHomology MedicinesNASDAQ:FIXXSol-Gel TechnologiesNASDAQ:SLGLTherapeuticsMDNASDAQ:TXMDXilio TherapeuticsNASDAQ:XLOView All CompetitorsInstitutional OwnershipSabby Management LLCSold 106,052 shares on 11/15/2023Ownership: 2.713%Group One Trading L.P.Bought 300 shares on 11/9/2023Ownership: 0.000%Cutler Group LLC CASold 1,000 shares on 11/7/2023Ownership: 0.000%View All Institutional Transactions BIOR Stock Analysis - Frequently Asked Questions Should I buy or sell Biora Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOR shares. View BIOR analyst ratings or view top-rated stocks. How have BIOR shares performed in 2023? Biora Therapeutics' stock was trading at $82.3125 at the start of the year. Since then, BIOR shares have decreased by 98.4% and is now trading at $1.35. View the best growth stocks for 2023 here. Are investors shorting Biora Therapeutics? Biora Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 653,700 shares, an increase of 28.6% from the October 31st total of 508,200 shares. Based on an average daily volume of 166,500 shares, the days-to-cover ratio is currently 3.9 days. Currently, 2.9% of the company's stock are short sold. View Biora Therapeutics' Short Interest. When is Biora Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our BIOR earnings forecast. How were Biora Therapeutics' earnings last quarter? Biora Therapeutics, Inc. (NASDAQ:BIOR) announced its earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.01. The firm had revenue of $0.18 million for the quarter, compared to analyst estimates of $11.10 million. During the same quarter last year, the firm earned ($1.01) earnings per share. When did Biora Therapeutics' stock split? Biora Therapeutics shares reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Biora Therapeutics' major shareholders? Biora Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sabby Management LLC (2.71%), Group One Trading L.P. (0.00%), Cutler Group LLC CA (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L, Damon Silvestry, Harry Stylli, Jeffrey D Alter and Surbhi Sarna. View institutional ownership trends. How do I buy shares of Biora Therapeutics? Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BIOR) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.